Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care

Tien M Truong, Jeffrey L Apfelbaum, Emily Schierer, Keith Danahey, Brittany A Borden, Theodore Karrison, Sajid Shahul, Magdalena Anitescu, Rebecca Gerlach, Randall W Knoebel, David O Meltzer, Mark J Ratain, Peter H O'Donnell, Tien M Truong, Jeffrey L Apfelbaum, Emily Schierer, Keith Danahey, Brittany A Borden, Theodore Karrison, Sajid Shahul, Magdalena Anitescu, Rebecca Gerlach, Randall W Knoebel, David O Meltzer, Mark J Ratain, Peter H O'Donnell

Abstract

Objectives: Integration of pharmacogenomics into clinical care is being studied in multiple disciplines. We hypothesized that understanding attitudes and perceptions of anesthesiologists, critical care and pain medicine providers would uncover unique considerations for future implementation within perioperative care.

Methods: A survey (multiple choice and Likert-scale) was administered to providers within our Department of Anesthesia and Critical Care prior to initiation of a department-wide prospective pharmacogenomics implementation program. The survey addressed knowledge, perceptions, experiences, resources and barriers.

Results: Of 153 providers contacted, 149 (97%) completed the survey. Almost all providers (92%) said that genetic results influence drug therapy, and few (22%) were skeptical about the usefulness of pharmacogenomics. Despite this enthusiasm, 87% said their awareness about pharmacogenomic information is lacking. Feeling well-informed about pharmacogenomics was directly related to years in practice/experience: only 38% of trainees reported being well-informed, compared to 46% of those with 1-10 years of experience, and nearly two-thirds with 11+ years (P < 0.05). Regarding barriers, providers reported uncertainty about availability of testing, turnaround time and whether testing is worth financial costs.

Conclusions: Anesthesiology, critical care and pain medicine providers are optimistic about the potential clinical utility of pharmacogenomics, but are uncertain about practical aspects of testing and desire clear guidelines on the use of results. These findings may inform future institutional efforts toward greater integration of genomic results to improve medication-related outcomes.

Trial registration: ClinicalTrials.gov NCT03729180.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Figures

Figure 1. Perceptions of degree to which…
Figure 1. Perceptions of degree to which providers feel informed about pharmacogenomics.
Shown are responses to the question “How informed do you feel about pharmacogenomics?” stratified by provider types (top panel) and years of experience (bottom panel). Very few providers felt very well-informed, regardless of provider type or years in practice, and the majority felt somewhat or very under-informed. With increasing number of years of practice, providers felt increasingly more informed about pharmacogenomics. MD-F: faculty physicians, MD-H: housestaff physicians, including fellows and residents. CRNA: certified registered nurse anesthetists. PharmD: pharmacists.

Source: PubMed

3
订阅